<DOC>
	<DOCNO>NCT00522145</DOCNO>
	<brief_summary>The purpose study determine best confirm response rate daily administration multiple receptor tyrosine kinase ( RTK ) inhibitor ( include EGFR VEGFR2 ) XL647 subject NSCLC progress respond treatment either erlotinib gefitinib .</brief_summary>
	<brief_title>Study XL647 Subjects With NSCLC Who Have Progressed After Responding Treatment With Gefitinib Erlotinib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically confirm diagnosis unresectable Stage IIIB Stage IV relapse recurrent NSCLC . Subjects must : 1. document ( radiological clinical ) progressive disease ( PD ) follow prior response ( include stable disease ) monotherapy erlotinib gefitinib administer least 12 week prior progression OR 2. document T790M EGFR mutation Measurable disease define accord RECIST ECOG performance status 0 1 . Sexually active subject must use accepted method contraception course study . Female subject childbearing potential must negative pregnancy test enrollment . Received radiation ≥25 % bone marrow within 30 day XL647 treatment . Received erlotinib gefitinib , anticancer therapy within 14 day first dose study drug . Received investigational drug ( exclude erlotinib gefitinib ) within 30 day first dose study drug . Receiving anticoagulation therapy warfarin . Not recover Grade ≤1 adverse event ( AEs ) due antineoplastic agent , investigational drug , medication administer prior study enrollment . Corrected QT interval ( QTc ) &gt; 0.45 second . Progressive , symptomatic , hemorrhagic brain leptomeningeal metastasis . Requires steroid anticonvulsant therapy treatment brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Non-Small-Cell Lung Cancer</keyword>
</DOC>